Martin Joyce Net Worth

The estimated Net Worth of Martin Joseph Joyce is at least $293 Thousand dollars as of 23 June 2022. Mr. Joyce owns over 4,323 units of Aldeyra Therapeutics Inc stock worth over $148,356 and over the last 11 years he sold ALDX stock worth over $0. In addition, he makes $144,556 as Independent Director at Aldeyra Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Joyce ALDX stock SEC Form 4 insiders trading

Martin has made over 5 trades of the Aldeyra Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 4,323 units of ALDX stock worth $15,044 on 23 June 2022.

The largest trade he's ever made was buying 12,500 units of Aldeyra Therapeutics Inc stock on 7 May 2014 worth over $100,000. On average, Martin trades about 1,598 units every 198 days since 2014. As of 23 June 2022 he still owns at least 23,967 units of Aldeyra Therapeutics Inc stock.

You can see the complete history of Mr. Joyce stock trades at the bottom of the page.

Martin Joyce biography

Martin J. Joyce serves as Independent Director of the Company. Mr. Joyce’s professional background includes leadership roles in public and private, medical device, biotechnology and pharmaceutical companies from start-up stage to over $500 million in annual revenue. He has experience in public equity financings, business development, SEC reporting, strategic planning, mergers, acquisitions, investor relations and biotechnology operations. Since 2012, Mr. Joyce has served as a consultant to the life science industry assisting biotechnology and pharmaceutical companies in strategic planning, fund raising and operations. From March 2011 to July 2012, Mr. Joyce was Chief Financial Officer at Lucid Inc., an early stage skin cancer diagnostic company. Previously, Mr. Joyce served as Executive Vice President and Chief Financial Officer of BioSphere Medical from January 2006 through September 2010. He served as BioSphere’s Chief Financial Officer and Vice President from September 2004 to January 2006. From January 2001 to September 2004, Mr. Joyce served as Managing Partner of Stratex Group LLC, a provider of biopharmaceutical executive services to early-stage companies and venture investors. From 1996 to January 2001, Mr. Joyce was North American Chief Financial Officer for Serono Inc. a biotechnology company. From April 1987 to 1996, Mr. Joyce held a variety of senior level positions within Serono in finance, sales, marketing and manufacturing. Mr. Joyce was previously employed at Millipore Corporation, a high technology bioscience company. Mr. Joyce received a B.S. in finance from Northeastern University and a M.B.A. from Suffolk University, Boston, Massachusetts. Mr. Joyce’s extensive knowledge of our business and history, experience in multiple publicly-traded and privately-held companies, and expertise in developing, financing and providing strong executive leadership to numerous biopharmaceutical companies contributed to our conclusion that he should serve as a director of our company.

What is the salary of Martin Joyce?

As the Independent Director of Aldeyra Therapeutics Inc, the total compensation of Martin Joyce at Aldeyra Therapeutics Inc is $144,556. There are 6 executives at Aldeyra Therapeutics Inc getting paid more, with Todd Brady having the highest compensation of $4,141,260.

How old is Martin Joyce?

Martin Joyce is 65, he's been the Independent Director of Aldeyra Therapeutics Inc since 2013. There are 3 older and 11 younger executives at Aldeyra Therapeutics Inc. The oldest executive at Aldeyra Therapeutics Inc is Jesse Treu, 73, who is the Independent Director.

What's Martin Joyce's mailing address?

Martin's mailing address filed with the SEC is C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, LEXINGTON, MA, 02421.

Insiders trading at Aldeyra Therapeutics Inc

Over the last 11 years, insiders at Aldeyra Therapeutics Inc have traded over $6,285,725 worth of Aldeyra Therapeutics Inc stock and bought 11,547,153 units worth $75,179,936 . The most active insiders traders include Advisors Llcperceptive Life..., & Johnson Johnson & Johnson..., and Advisors Llcedelman Josephp.... On average, Aldeyra Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $1,358,662. The most recent stock trade was executed by Stephen Machatha on 12 August 2024, trading 16,041 units of ALDX stock currently worth $76,034.

What does Aldeyra Therapeutics Inc do?

dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise

Complete history of Mr. Joyce stock trades at Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc executives and stock owners

Aldeyra Therapeutics Inc executives and other stock owners filed with the SEC include:

• Todd Brady,
  President, Chief Executive Officer, Director
• Joshua Reed,
  Chief Financial Officer
• David McMullin,
  Chief Commercial Officer
• Dr. Todd C. Brady M.D., Ph.D.,
  CEO, Pres & Director
• Joshua Reed M.B.A.,
  Chief Financial Officer
• Richard Douglas,
  Independent Chairman of the Board
• Martin Joyce,
  Independent Director
• Jesse Treu,
  Independent Director
• Ben Bronstein,
  Independent Director
• Gary Phillips,
  Independent Director
• Neal Walker,
  Independent Director
• Scott Solomon,
  IR Contact Officer
• Nancy Miller-rich,
  Independent Director
• Stephen Machatha,
  Senior Vice President, Technical Operations
• James Gow,
  Senior Vice President - Clinical Development
• Bruce Greenberg CPA, M.B.A.,
  VP & Controller
• Dr. Stephen G. Machatha Ph.D.,
  Chief Devel. Officer
• Kelly Mizer,
  VP of Commercial Strategy & Operations
• David J Clark,
  Chief Medical Officer
• Advisors Llcedelman Josephp...,
  
• C. Boyd Clarke,
  Director
• Stephen J Tulipano,
  Chief Financial Officer
• Scott Young,
  Chief Operating Officer
• Bruce Greenberg,
  See Remarks
• Advisors Llcperceptive Life...,
  
• Partners Vi, L.P.Blair Jame...,
  
• & Johnson Johnson & Johnson...,
  
• Vi Associates, L.P.Blair Ja...,